Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers propose using a less-than-one-in-a-million level—or the absence of minimal residual disease—to measure drugs’ effectiveness.
Researchers called the results of treatment using Venclexta (venetoclax) and Vidaza (azacitidine) “remarkably impressive.”
Q&A: Riki Peters, PhD, MPH, on what this large genome-wide association study means for patients and the public
One hundred twenty volunteers to enroll in Seattle-area study of cancer-related gene mutations
Researchers studied older women with breast cancer to discover why some people are particularly susceptible to “chemo brain.”
Patients and providers must have the evidence that they need and deserve to inform effective medical care.
Turns out mutations in the TP53 gene are focused on so-called “hot spots” because specific carcinogens target those spots.
Cancer geneticists, epidemiologists and oncologists team up to use mutation rate to predict individual cancer risk.
The study used two FDA-approved drugs to the pre-leukemic cells while leaving healthy stem cells alone.
Pilot study suggests specific strain of bacteria may be found more often in East Asian patients with stomach cancer.
Though researchers knew that exosomes play important roles in cancer and in the immune system, only now are they learning the specifics.
The findings lay the groundwork for tests that can identify whether the disease is likely to progress rapidly.
“It stands to reason that we should develop treatments specifically for appendix cancer.”
A conversation with Dr. Charles Modlin of the Cleveland Clinic about the MENtion It survey
A common mutation makes mouse tumors more vulnerable to certain cancer drugs.
Researchers say it would be ideal to have future clinical trials in which tissue-based biomarker studies dictate treatment options.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.